Efficacy and Safety of Ceftazidime-Avibactam Alone versus Ceftazidime-Avibactam Plus Fosfomycin for the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia: A Multicentric Retrospective Study from the SUSANA Cohort

• Main Authors: Marco Fois (Author), Andrea De Vito (Author), Francesca Cherchi (Author), Elena Ricci (Author), Michela Pontolillo (Author), Katia Falasca (Author), Nicolò Corti (Author), Agnese Comelli (Author), Alessandra Bandera (Author), Chiara Molteni (Author), Stefania Piconi (Author), Francesca Colucci (Author), Paolo Maggi (Author), Vincenzo Boscia (Author), Aakash Fugooah (Author), Sara Benedetti (Author), Giuseppe Vittorio De Socio (Author), Paolo Bonfanti (Author), Giordano Madeddu (Author)
• Format: Book
• Published: MDPI AG, 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Hospital-acquired pneumonia (HAP) and ventilation-associated pneumonia (VAP) are challenging clinical conditions due to the challenging tissue penetrability of the lung. This study aims to evaluate the potential role of fosfomycin (FOS) associated with ceftazidime/avibactam (CZA) in improving the ou...